Article
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
2025-07-21
Abstract excerpt
<h4>Background</h4> Cancers that do not respond to immunotherapy typically harbor a non-T cell-inflamed tumor microenvironment (TME), characterized by the absence of type I/II interferon (IFN) signaling and CD8 + T cell infiltration. We previously reported IDH1 somatic mutations were enriched in non-T cell-inflamed tumors across tumor types. Consistent with this, mutant IDH1 (mIDH1) has been demonstrated to dri...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 366792c7-ee48-53aa-8a96-293e77e1d57f
- DOI
- 10.1101/2025.07.19.25331848